<p>Aging causes gradual and significant declines in immune functions and responses. However, the impact of aging on the immunotherapy outcomes in advanced renal cell carcinoma is largely unknown. Here, we conducted a pooled analysis of individual participant data from two regulatory-approved randomized controlled trials: CheckMate 214 and JAVELIN Renal 101. The overall population (n=1926) included 964 individuals treated with immune…
Aging is associated with the outcomes of immune checkpoint blockade in renal cell carcinoma
Journal for ImmunoTherapy of Cancer | | Huang, Z., Zhou, J., Zheng, Z., Zhao, H., Zhao, B., Zeng, R.
Topics: blood-cancer, kidney-cancer, cervical-cancer, immunotherapy, clinical-trials
Read the full article at Journal for ImmunoTherapy of Cancer